You searched for: leverfunktionsabnormaliteter (Danska - Engelska)

patienter med eksisterende leverdysfunktion, inkl. kronisk aktiv hepatitis har øget frekvens af leverfunktionsabnormaliteter under antiretroviral kombinationsbehandling og bør monitoreres i henhold til gældende praksis.
patients with pre-existing liver dysfunction including chronic active hepatitis have an increased frequency of liver function abnormalities during combination antiretroviral therapy and should be monitored according to standard practice.

patienter med før-eksisterende leverfunktionssvigt inklusive kronisk aktiv hepatitis har en højere risiko for leverfunktionsabnormaliteter under antiretroviral kombinationsbehandling og bør monitoreres ifølge standard i praksis.
patients with pre-existing liver dysfunction including chronic active hepatitis have an increased frequency of liver function abnormalities during combination antiretroviral therapy and should be monitored according to standard practice.

patienter med eksisterende leverdysfunktion, inkl. kronisk aktiv hepatitis har øget frekvens af leverfunktionsabnormaliteter under antiretroviral kombinations-behandling og bør monitoreres i henhold til gældende praksis.
patients with pre-existing liver dysfunction including chronic active hepatitis have an increased frequency of liver function abnormalities during combination antiretroviral therapy and should be monitored according to standard practice.

viramune må ikke genadministreres til patienter, som tidligere havde asat eller alat 5 uln under viramunebehandling og havde tilbagevenden af leverfunktionsabnormaliteter efter genadministration af viramune (se pkt..4. 4) .
viramune must not be readministered in patients who previously had asat or alat 5 uln during viramune therapy and had recurrence of liver function abnormalities upon readministration of viramune (see section 4.4) .

viramune må ikke genadministreres til patienter, som tidligere havde asat eller alat 5 uln under viramune-behandling og havde tilbagevenden af leverfunktionsabnormaliteter efter genadministration af viramune (se pkt..4. 4) .
viramune must not be readministered in patients who previously had asat or alat 5 uln during viramune therapy and had recurrence of liver function abnormalities upon readministration of viramune (see section 4.4) .